Published in final edited form as:

Chem Sci. 2012 January 1; 3(12): 3378–3386. doi:10.1039/C2SC21308G.

Fusarisetin A: Scalable Total Synthesis and Related Studies

Jing Xu^{a,†}, Eduardo J.E. Caro-Diaz^{a,‡}, Michelle H. Lacoske^a, Chao-I. Hung^a, Colin Jamora^b, and Emmanuel A. Theodorakis^a

Emmanuel A. Theodorakis: etheodor@ucsd.edu

^aDepartment of Chemistry & Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0358, USA

^bSection of Cell and Developmental Biology and Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0752, USA

Abstract

Fusarisetin A (**1**) is a recently isolated natural product that displays an unprecedented chemical motif and remarkable bioactivities as a potent cancer migration inhibitor. We describe here our studies leading to an efficient and scalable total synthesis of **1**. Essential to the strategy was the development of a new route for the formation of a *trans*-decalin moiety of this compound and the application of an oxidative radical cyclization (ORC) reaction that produces fusarisetin A (**1**) from equisetin (**2**) via a bio-inspired process. TEMPO-induced and metal/O₂-promoted ORC reactions were evaluated. Biological screening *in vitro* confirms the reported potency of (+)-**1**. Importantly, *ex vivo* studies show that this compound is able to inhibit different types of cell migration. Moreover, the C₅ epimer of (+)-**1** was also identified as a potent cancer migration inhibitor, while (–)-**1** and **2** were found to be significantly less potent. The optimized synthesis is applicable on gram scale and provides a solid platform for analogue synthesis and methodical biological study.

Introduction

Despite the tremendous advances, cancer still represents an enormous medical challenge since, only in America, it is responsible for more than half a millions of deaths per year.¹ About 90% of these deaths are attributed to cancer metastasis, which is the ability of tumor cells to migrate from their tissue of origin and colonize elsewhere in the body.² When cancer is detected at a premetastatic stage, it can often be treated successfully either by local therapy (surgery, radiation) or by systemic therapy (chemotherapy, targeted therapy, hormonal therapy).³ However, when it is detected after it has metastasized, such treatments are much less successful. Along these lines, metastasis is considered as the “last frontier” in cancer management for which, to-date, there is no effective treatment.^{4,5}

In principle, it is possible to halt (or retard) cancer metastasis with the help of small molecules that inhibit cell migration.⁶ Recent advances in high-throughput screening and high content imaging techniques permit the identification of new cancer metastasis inhibitors from libraries of natural products or small molecules.^{7,8} On the other hand, the availability of complex natural products via improved isolation techniques and streamlined

© The Royal Society of Chemistry

Correspondence to: Colin Jamora; Emmanuel A. Theodorakis, etheodor@ucsd.edu.

[†]These authors contributed equally.

Dedicated with respect and appreciation to Professor Paul A. Wender on the occasion of his 65th birthday.

[†]Electronic Supplementary Information (ESI) available: Experimental details and spectroscopic characterizations. See DOI: 10.1039/b000000x/

synthetic strategies (or genetic engineering) allows evaluation of their effect in cell migration assays. Scepterin⁹ and migrastatin¹⁰ represent a few recent examples of such efforts. Importantly, the development of scalable syntheses of these compounds^{11,12} have resulted in the development of new chemical tools for the study of proteins involved in cancer metastasis and the discovery of potent cell migration inhibitors for further preclinical studies.^{11b,12c,d}

Recent efforts to identify potent inhibitors of cancer metastasis have led to the isolation of fusarisetin A (**1**) from a *Fusarium* species (Figure 1).¹³ This compound was found to inhibit cancer metastasis in MDA-MB-231 cells, a particularly aggressive breast cancer cell line. Specifically, **1** was found to inhibit acinar morphogenesis (IC₅₀ ca 77 μ M), cell migration (IC₅₀ ca 7.7 μ M) and cell invasion (IC₅₀ ca 26 μ M) in these cell lines without any significant cytotoxicity in concentrations up to 77 μ M. Interestingly, the proteomic profiling of **1** was found to be significantly different to those of other reference compounds. Moreover, **1** did not inhibit the phosphorylation of ERK1/2, AKT, c-Jun and p38 kinases in response to EGF treatment, as it is commonly observed with compounds that inhibit cancer metastasis by altering protein kinases.⁶ These findings suggest that the molecular target of fusarisetin A is different from those of known compounds and thus, its identification could produce new fundamental knowledge in the signal transduction pathways related to cancer metastasis. From a chemistry standpoint, fusarisetin A possesses an unprecedented pentacyclic ring system of which the CDE rings contain various polar functionalities (ketone, lactam, hemiketal and primary alcohol). The combination of impressive chemical structure and potent bioactivity is evidenced by the three publications describing various syntheses of **1** in about one year after its structure became known in the literature.^{14,15,16} Intrigued by this molecule, we devised a project focused on the development of a scalable chemical synthesis that may allow the study of its chemical biology. Herein we report a detailed account on the synthesis of fusarisetin A. The developed strategy is short, efficient and stereoselective and is highlighted by the use of a key oxidative radical cyclization (ORC) reaction that allows conversion of equisetin (**2**) to fusarisetin A (**1**) following a likely biosynthetic pathway. Moreover, our biological studies confirm the reported bioactivity of **1** *in vitro* and indicate that this activity is maintained in whole tissue using *ex vivo* assays.

Results and discussion

Retrosynthetic analysis and strategic bond disconnections

Close inspection of the fusarisetin framework reveals the fusion of a *trans*-decalin unit (AB ring system) with a tetramic acid moiety (E ring). These rings can also be found in the structure of equisetin (**2**),¹⁷ another secondary metabolite produced by a *Fusarium* species, suggesting that both molecules may arise from a common biosynthetic pathway (Figure 1).¹⁸ Along these lines, we hypothesized that **1** derives biogenetically from oxidation of **2** upon exposure to reactive oxygen species (ROS).¹⁹ This biosynthetic scenario could account for the formation of stabilized radical **3** that, upon cyclization at the pendant alkene followed by trapping by ROS and hemiketalization, would produce **1**. Translating this proposal to a synthetic plan, we envisioned that equisetin could undergo a 5-*exo-trig* oxidative radical cyclization (ORC)²⁰ to form the C₁–C₆ bond. The resulting C₅ radical could then be trapped by oxygen or a related ROS. Further bond disconnection of the equisetin motif suggested that **2** could be produced from β -ketoester **4**, the *trans*-decalin motif of which (AB ring system) could be made via an intramolecular Diels-Alder reaction (IMDA).²¹ This scenario led to consider polyene **5** as the potential precursor of the IMDA. In turn, **5** could be synthesized from commercially available citronellal (**6**) whose motif contains the C₂₁ methyl group with the desired stereochemistry.²²

Synthesis of the *trans*-decalin moiety and evaluation of the TEMPO-induced ORC

The retrosynthetic plan shown in Figure 1 calls for departure of the synthesis from (*R*)-(+)-citronellal (**6**). Nonetheless, guided by the original assignment of fusarisetin A,¹³ we started our synthesis with commercially available (*S*)-(–)-citronellal (**ent-6**) (Scheme 1).²³ Inspiration for our studies came from previously reported syntheses of equisetin by the Danishefsky, Dixon and Shishido groups.²⁴ With an eye toward step-economy,²⁵ we sought to develop an alternative synthesis of this compound. To this end, **ent-7** was synthesized from **ent-6** via cross-metathesis with methacrolein using a Ru-carbene catalyst (Grubbs 2nd generation, 5 mol%)²⁶ (75% yield). Alternatively, allylic oxidation of **ent-6** with SeO₂/IBX can also form **ent-7** in 65% yield. Although both reactions are scalable, in our subsequent studies we used the SeO₂/IBX method due to its lower cost. The two chemically differentiable carbonyl groups of this compound provide the possibility to install the polyene motif in a regioselective manner. Initial olefination studies of **ent-7** under HWE or Julia conditions proved to be unsatisfactory.^{24b–c,27} However, slow addition of the Wittig ylide, generated upon deprotonation of phosphonium salt **8**,²⁸ to **ent-7** afforded polyene **ent-5** in 62% overall yield as a mixture of *E/Z* isomers (*E:Z* = ca 3:2). Photo-induced isomerisation of this mixture with catalytic amount of iodine²⁹ produced exclusively the *trans* polyene. Without purification, this compound was subjected to a Et₂AlCl-promoted IMDA reaction, that stereoselectively produced the desired *trans*-decalin aldehyde **ent-9** (dr > 10:1, 82% yield). It is noted that the rapid construction of this *trans*-decalin motif could grant access to other biologically interesting natural products.³⁰ Treatment of **ent-9** with ethyl bromoacetate under Reformatsky conditions followed by IBX oxidation yielded β-keto ester **ent-4** in 91% combined yield. Aminolysis of this compound with serine derivative **ent-10**, followed by deprotection of the TBS group, produced **ent-11** (43% yield overall). Dieckmann condensation of **ent-11** produced a mixture of (+)-equisetin (**ent-2**) together with its C₃-epimer (**ent-C₃-epi-2**) (100% yield, dr = 1:1).²² It should be noted that the tendency of equisetin to epimerize at the C₃ center under basic conditions has been previously reported³¹ and has been observed consistently in our studies. Low temperature ¹H NMR experiments have also confirmed that equisetin exists exclusively in the enol form and not as a tautomeric mixture as recently reported.¹⁶ The structures of these compounds were also confirmed by comparison with the known data.^{16,17,24,31}

With **ent-2** in hand, we sought to explore ORC processes for the formation of the C ring of fusarisetin. It is worth noting that although radical reactions have often been used in natural products synthesis for the construction of C–C bonds,³² their application to the formation of C–O bonds remains limited.³³ A report by Jahn *et al* on the construction of 5-membered rings, using 1,3-dicarbonyl groups and alkenes under TEMPO conditions, provided a possible way for the desired transformation.³⁴ However, our initial studies with **ent-2** gave unsatisfactory results, presumably due to the sensitivity of its C₃ hydroxymethyl group. To overcome this issue, we protected equisetin as its TBS ether **ent-12** (90% yield). Gratifyingly this compound underwent the desired ORC, using ferrocenium hexafluorophosphate (**13**) or Mn(III) acetate as the oxidants,³⁵ to afford cyclized TEMPO-product **ent-14** albeit in moderate yield (35%). Mechanistically, this reaction proceeds via a heat-promoted homolytic cleavage of the TEMPO–C₁ bond.³⁶ The resulting stabilized radical at C₁ reacts with the pendant C₅–C₆ alkene to generate the C₅-radical that can subsequently be trapped by the available TEMPO.³⁷ Reduction of the alkoxyamine bond of **ent-14** under Zn/AcOH conditions³⁸ liberated the C₅-alcohol that underwent the desired hemiketalization, along with concomitant deprotection of the TBS group, to form a compound that was spectroscopically identified as the C₅-epimer of (–)-fusarisetin A (**ent-C₅-epi-1**).¹⁴

The results of this study allowed us to draw several conclusions related to the TEMPO-mediated ORC reaction. As predicted, the TEMPO can indeed act as an ROS synthetic alternative and could form the C ring of **ent-14** albeit in low yield. Gratifyingly, the stereochemistry of the C₁–C₆ bond was efficiently controlled by the structure of the decalin ring. Unfortunately, the stereochemistry of the C₅ center was not the desired one. Moreover, we encountered difficulties applying this reaction to a non-protected equisetin (**ent-2**). These considerations prompted us to apply the TEMPO-mediated ORC on a less functionalized substrate.

Total synthesis of (–)-fusarisetin A (**ent-1**)

β-Keto ester **ent-4** appeared to be an attractive substrate for the TEMPO-mediated ORC, since it is less functionalized than equisetin and also contains an easily oxidizable C₁ center. With this in mind, **ent-4** was treated with LiHMDS and the resulting C₁ enolate was *in situ* oxidized with **13** to afford, after quenching of the C₁ radical with TEMPO, compound **ent-15**. As expected, under these conditions (5 min, 0 °C) the ORC did not occur and **ent-15** was isolated and fully characterized as a mixture of C₁-isomers (ca 2.5:1) in 99% yield. Heating this isomeric mixture at 90 °C over a period of 36 h gave rise to the tricyclic motif of **ent-16** via the desired 5-*exo-trig* cyclization. Similarly with the above study, the formation of the C₁–C₆ bond proceeded with excellent stereocontrol, presumably due to the stereochemical bias of the decalin motif. Interestingly however, in this case we obtained a mixture of stereoisomers at C₅ (ca 1:1). It is worth mentioning that attempts to decrease the reaction time by raising the temperature proved to be problematic since they led to significant amounts of decarboxylated product **ent-17**. To further enhance the overall efficiency, we also examined the one-pot ORC and aminolysis sequence in presence of serine derivative **ent-18**. To our delight, this one-pot reaction gave rise to compound **ent-19** (C₅ dr = ca 1:1) in 70% overall yield. To avoid the difficult separation of these diastereomers, **ent-19** was directly treated with *m*-CPBA³⁹ to oxidatively cleave the *N*-O bond producing **ent-20** in 95% yield. Regio- and stereo-selective reduction of this compound under Luche conditions^{40,14} followed by a one-pot Dieckmann condensation/hemiketalization yielded (–)-fusarisetin A (**ent-1**) together with its C₅-epimer (dr = ca 4:1, 42% over 2 steps). Synthetic (–)-fusarisetin A was identical in all aspects with naturally occurring fusarisetin A (¹H-NMR, ¹³C-NMR and HR-MS), except for the optical rotation (synthetic: [α]_D²³ = –86.2 (c = 0.065 in MeOH); natural: [α]_D²⁵ = +84.6 (c = 0.2 in MeOH)¹³, reported synthetic (–)-**1**: [α]_D²⁷ = –88.0 (c = 0.15 in MeOH).¹⁴ The structure of **ent-C5-epi-1** was confirmed by comparison to the literature data.^{14,16}

Model studies on the metal-promoted ORC

Despite the overall efficiency of the one-pot TEMPO-mediated ORC/aminolysis reaction, the scale-up process suffers from significant decarboxylation of β-ketoester **ent-16**. Faced with this challenge, we evaluated alternative metal-promoted ORC reactions. To this end, we synthesized model system **24** that contains all key carbons needed for the proposed cyclization (Scheme 3). This compound was prepared via a sequence of 3 steps that included: (a) kinetic alkylation⁴¹ of ethyl acetoacetate (**21**) with crotyl bromide to form **22**; (b) aminolysis of the ester group with *N*-methyl glycine methyl ester to produce **23**; and (c) Dieckmann condensation (formation of the C₁–C₄ bond) to yield **24** (45% yield overall). Tetramic acid **24** was then subjected to various reagents and conditions in order to perform the desired ORC (Table 1). Scarce literature reports³³ indicate the feasibility of this transformation that, nonetheless, has never been applied to intramolecular systems or any natural product synthesis. It is known that certain high oxidation state metals, such as Mn(III), Co(II), Ag(II), Pd(II), Pb(IV) and Ce(III), can promote the addition of carbon radicals derived from ketones to alkenes.^{20,42} On the other hand, molecular oxygen exists as a persistent triplet diradical in its ground state and as such it can react rapidly with carbon-

centered radicals.⁴³ With this in mind, we treated **24** with various metals in the presence of O₂ and, in certain cases, were able to isolate peroxyhemiketal **25** (as C₅ isomers). Reduction of the peroxide motif of **25** then produced **26** (as C₅ isomers) representing the tricyclic core of fusarisetin A.

The nature of the metal oxidant, oxygen pressure and reaction solvent/time were screened in order to optimize this ORC. Initial encouraging results were obtained using cobalt(II) acetate/AcOH/O₂ (1 bar) and afforded the desired *cis*-peroxyhemiketal **25** as a mixture of C₅ diastereomers (ratio 2:1) albeit in low yield (20%). Reduction of the cyclic peroxide group of **25** with CuCl yielded the corresponding tricyclic compounds **26a** and **26b** (ratio 2:1) in 80% overall yield (Table 1, entry 1).⁴⁴ Lower reaction temperature or replacement of the solvent/reductant led to unsatisfactory results (Table 1, entries 2–4). More than 20 metal or non-metal based oxidants were then further screened (see SI) under AcOH/O₂ conditions. Mn(III)-, Fe(III)- and Ce(III)-based oxidations were found to be inefficient for the conversion of **24** to **25** (Table 1, entries 6–8). Gratifyingly, cerium(IV) ammonium nitrate (CAN) significantly increased the yield of **25** to 57% (Table 1, entry 9). Decreasing the reaction temperature did not affect the diastereoselectivity at C₅ (Table 1, entry 10), while higher temperatures decreased the yield (Table 1, entry 11). Air or catalytic amounts of CAN (10 mol%) can also be used for the conversion of **24** to **25** but in this case the formation of **25** is low yielding (Table 1, entries 12–13). Nonetheless, in all cases the reaction proceeded in a highly stereocontrolled manner affording only two of eight possible diastereomers (ratio ca 1.5:1 ~ 2:1).⁴⁴ It is worth mentioning that, independently of this study, Gao *et al* recently reported the conversion of (–)-equisetin to (+)-fusarisetin A using Mn(III)/O₂ conditions.¹⁶

Total synthesis of (–)-equisetin (**2**) and (+)-fusarisetin A (**1**)

Encouraged with the above results, we proceeded to implement the optimized ORC conditions to the synthesis of (+)-fusarisetin A using (–)-equisetin as the key synthetic intermediate (Scheme 4). Aldehyde **9** was rapidly and stereoselectively constructed from (*R*)-citronellal (**6**) in decagram-scale (35% over 3 steps) following the above procedure. Conversion of **9** to **4** proceeded under Reformatsky conditions followed by oxidation of the resulting alcohol with Dess-Martin periodinane (2 steps, 92% overall yield, ca 7 grams prepared). It is worth noting that at this scale the IBX oxidation produced significant amounts of decarboxylated material. Aminolysis of ester **4** under various conditions, such as DMAP^{14,15} and NHC-based reagents,⁴⁵ with *N*-methyl serine methylester (**18**)⁴⁶ afforded **11** in low yield. However, mild hydrolysis of **4** with ethanolic KOH (rt, 96 h) quantitatively produced the corresponding carboxylic acid that, upon coupling with **18** under HATU conditions afforded the desired amide **11** in 90% yield. Dieckmann condensation of **11** quantitatively produced a mixture of (–)-equisetin (**2**) and C₃-*epi*-equisetin (C₃-*epi*-**2**) (100%, dr = ca 1:1).^{16,17,24,31}

Gratifyingly, the previously defined ORC conditions were successfully applied for the conversion of (–)-equisetin (**2**) to (+)-fusarisetin A (**1**). Specifically, oxidation of **2** under CAN/AcOH/O₂ conditions produced an inseparable mixture of peroxy-fusarisetin A (**27**) and its C₅ epimer (C₅-*epi*-**27**) (dr = 1.3:1). This mixture was further reduced with thiourea (10 equiv) to afford (+)-fusarisetin A (**1**) together with its C₅ epimer (C₅-*epi*-**1**) (62% overall, dr = 1.3:1).⁴⁷ The structures of both C₅ epimers of **27** and **1** have been confirmed by ¹H-NMR, ¹³C NMR and HR-MS analysis.^{13–16} As observed previously, the stereoselectivity of this ORC reaction is substrate-controlled and affords the desired stereochemistry at the C₁ and C₆ centers.

We were also able to use the mixture of equisetin (**2**) and C₃-*epi*-equisetin (C₃-*epi*-**2**) in the ORC reaction. In fact, 1.1 grams of this mixture (dr = 1:1) were treated under CAN/AcOH/O₂ conditions and the resulting crude mixture of peroxy-fusarisetins was reduced with excess thiourea. Purification of this mixture produced 200 mg of (+)-fusarisetin A (**1**). Notably, the whole synthetic process from decalin **9** to (+)-fusarisetin A was performed on gram-scale and requires only one purification via column chromatography. In summary, the syntheses of both **1** and **2** are scalable, redox-/step-economic and protecting-group free.⁴⁸

Biological studies of **1**, **2** and related structures

To confirm and expand upon the previously reported findings, we evaluated the biological activity of (+)-fusarisetin A (**1**) in a scratch-wound assay and in a Boyden Chamber Transwell assay. The first assay (Figure 2) involves inflicting a scratch wound in a confluent cell monolayer and measuring the migration of cells.⁴⁹ We were pleased to find that synthetic **1** inhibited migration of these cells at concentrations as low as 1 µg/mL (Figure 2C) as compared to vehicle control (Figure 2B). Importantly, removing **1** from the cells followed by incubation with fresh growth media allowed cells to migrate in a similar fashion to the control experiment (Figure 2D). This observation demonstrates that the effect of **1** on these cells is reversible, in turn suggesting that (+)-fusarisetin A has little to no cytotoxicity at 1 µg/mL concentration.

We then performed Transwell migration assays using increasing concentrations of **1** normalized with the appropriate DMSO controls. This assay measures the capacity of cells to migrate across a porous membrane using serum-rich media as a chemo-attractant.⁵⁰ As seen in Figure 3, cell migration was significantly inhibited at 3.0 and 6.0 µg/mL, while almost complete inhibition is observed at 12.0 µg/mL. Even at this concentration we did not observe any changes in the cell morphology, suggesting that **1** exhibits low cytotoxicity. The results of these two assays confirm the reported biological activity of fusarisetin A *in vitro*.

Encouraged by these findings, we then evaluated (+)-fusarisetin A in an *ex vivo* assay measuring migration of cells from a 5 mm mouse skin biopsy (Figure 4).⁵¹ We observed that both keratinocyte and fibroblast migration is inhibited upon exposure to **1** (10 µg/mL). Specifically, a substantial amount of cell migration is observed 5 days after plating the skin explant (Figure 4B), as compared to the initial time of plating (Figure 4A). In contrast, when explants were exposed to 10 µg/mL of **1** (Figure 4C), there was no detectable migration of keratinocytes from the explants, while fibroblast migration was reduced by approximately 80%. The observed ability of fusarisetin A to inhibit cell migration from skin explants is particularly exciting. The migration of fibroblasts is an example of mesenchymal cell migration whereas keratinocytes move via collective cell migration.⁵² Interestingly, compounds that target one type of migration have had disappointing results in clinical studies as the cancer cells are able to adapt and switch between different modes of migration.⁵³ Since fusarisetin A can significantly inhibit both types of migratory behavior, it could provide a powerful tool to circumvent the ability of cancer cells to alter their mode of motility if one pathway is inhibited.

Having demonstrated the cell-migration inhibitory properties of **1** both *in vitro* and *ex vivo* we then screened selected compounds containing the fusarisetin framework using the scratch-wound assay.⁵⁴ We observed that natural (–)-equisetin (**2**) and its enantiomer *ent*-**2** do not exhibit any activity at the concentrations tested (Figure 5). Similarly, *ent*-fusarisetin A (*ent*-**1**) was found to be inactive. However, the C₅ epimer of natural fusarisetin A (C₅-*epi*-**1**) was found to display similar activity to that of (+)-**1**. These initial findings attest to the importance of the CDE ring structure and suggest that only the naturally occurring

enantiomer of fusarisetin A could be used as a motif for the identification of new inhibitors of cell migration.

Conclusions

We report here a concise, efficient, and protecting group-free synthesis of fusarisetin A (**1**). Key to our synthetic strategy is the implementation of a bioinspired oxidative radical cyclization (ORC) reaction that forms the C ring of **1** via stereoselective construction of the C₁–C₆ bond. Subsequent oxidation at the C₅ center allows formation of the D ring of **1** ultimately converting equisetin (**2**) to fusarisetin A (**1**). The TEMPO-mediated ORC reaction could be successfully applied for the conversion of β -ketoester **4** to a tricyclic motif **19** that, upon Dieckmann condensation/ hemiketalization, formed fusarisetin (**1**) together with its C₅ epimer (*C*₅-*epi*-**1**). However, treatment of equisetin under these conditions produced exclusively the C₅ epimer of fusarisetin A (*C*₅-*epi*-**1**). On the other hand, metal-mediated ORC reactions, such as Co(OAc)₂, Mn(OAc)₃, ferrocenium- and cerium(IV)-salts, could be successfully applied in a model system for the construction of the CDE ring of **1**. Moreover, the conversion of **2** to **1** was best achieved using CAN/AcOH/O₂. Overall, the optimized synthesis of (+)-fusarisetin A proceeds in 8 steps and about 5% yield starting from commercially available *R*-(+)-citronellal. We have also confirmed that (+)-fusarisetin A exhibits potent inhibitory activities against cancer metastasis *in vitro* and demonstrated its capability to inhibit different types of cell migration in mice skin. Interestingly, equisetin (either enantiomer) and (–)-fusarisetin A were found to be inactive in these assays, while *C*₅-*epi*-**1** displayed comparable activities to that of the natural product. In turn, this suggests that the motif of (+)-fusarisetin A could lead to new potent cancer metastasis inhibitors. The scalable synthetic strategy presented here could pave the way for more detailed structure-activity relationship and chemical biology studies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the National Institutes of Health (NIH) for financial support of this work through Grant Number R01 GM081484. We thank the National Science Foundation for instrumentation grants CHE9709183 and CHE0741968. We also thank Dr. Yongxuan Su (UCSD MS Facility), Dr. Anthony Mrse (UCSD NMR Facility) and Dr. L. Trzoss for technical help and beneficial discussions.

References

1. (a) Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. CA-Cancer J. Clin. 2011; 61:69–90. [PubMed: 21296855] (b) <http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012>
2. Chaffer CL, Weinberg RA. Science. 2011; 331:1559–1564. [PubMed: 21436443]
3. (a) Coghlin C, Murray GI. J. Pathol. 2010; 222:1–15. [PubMed: 20681009] (b) Chambers AF, Groom AC, MacDonald IC. Nat. Rev. Cancer. 2002; 2:563–572. [PubMed: 12154349]
4. (a) Bacac M, Stamenkovic I. Annu. Rev. Pathol.- Mech. Dis. 2008; 3:221–247. (b) Chiang AC, Massague J. New Engl. J. Med. 2008; 359:2814–2823. [PubMed: 19109576]
5. (a) Talmadge JE, Fidler IJ. Cancer Res. 2010; 70:5649–5669. [PubMed: 20610625] (b) Elvin P, Garner AP. Curr. Opin. Pharmacol. 2005; 5:374–381. [PubMed: 15955738]
6. Sawyer TK. Exp. Opin. Invest. Drugs. 2004; 13:1–19.
7. Metaferia BB, Chen L, Baker HL, Huang XY, Bewley CA. J. Am. Chem. Soc. 2007; 129:2434–2435. [PubMed: 17295491]

8. (a) Valster A, Tran NL, Nakada M, Berens ME, Chan AY, Symons M. *Methods*. 2005; 37:208–215. [PubMed: 16288884] (b) Hulkower KI, Herber RL. *Pharmaceutics*. 2011; 3:107–124.
9. Walker RP, Faulkner DJ, Vanengen D, Clardy J. *J. Am. Chem. Soc.* 1981; 103:6772–6773.
10. Nakae K, Yoshimoto Y, Sawa T, Homma Y, Hamada M, Takeuchi T, Imoto M. *J. Antibiot.* 2000; 53:1130–1136. [PubMed: 11132958]
11. (a) Baran PS, Zografos AL, O'Malley DP. *J. Am. Chem. Soc.* 2004; 126:3726–3727. [PubMed: 15038721] (b) Cipres A, O'Malley DP, Li K, Finlay D, Baran PS, Vuori K. *ACS Chem. Biol.* 2010; 5:195–202. [PubMed: 20030414] (c) Birman VB, Jiang XT. *Org. Lett.* 2004; 6:2369–2371. [PubMed: 15228281] (d) Baran PS, Li K, O'Malley DR, Mitsos C. *Angew. Chem. Int. Ed.* 2006; 45:249–252. (e) O'Malley DP, Li K, Maue M, Zografos AL, Baran PS. *J. Am. Chem. Soc.* 2007; 129:4762–4775. [PubMed: 17375928]
12. (a) Gaul C, Njardarson JT, Danishefsky SJ. *J. Am. Chem. Soc.* 2003; 125:6042–6043. [PubMed: 12785819] (b) Njardarson JT, Gaul C, Shan D-D, Huang X-Y, Danishefsky SJ. *J. Am. Chem. Soc.* 2004; 126:1038–1040. [PubMed: 14746469] (c) Oskarsson T, Nagorny P, Krauss IJ, Perez L, Mandal M, Yang GL, Ouerfelli O, Xiao DH, Moore MAS, Massague J, Danishefsky SJ. *J. Am. Chem. Soc.* 2010; 132:3224–3228. [PubMed: 20155906] (d) Lecomte N, Njardarson JT, Nagorny P, Yang GL, Downey R, Ouerfelli O, Moore MAS, Danishefsky SJ. *P. Natl. Acad. Sci. USA.* 2011; 108:15074–15078.
13. Jang JH, Asami Y, Jang JP, Kim SO, Moon DO, Shin KS, Hashizume D, Muroi M, Saito T, Oh H, Kim BY, Osada H, Ahn JS. *J. Am. Chem. Soc.* 2011; 133:6865–6867. [PubMed: 21500849]
14. Deng J, Zhu B, Lu ZY, Yu HX, Li A. *J. Am. Chem. Soc.* 2012; 134:920–923. [PubMed: 22239597]
15. Xu J, Caro-Diaz EJ, Trzoss L, Theodorakis EA. *J. Am. Chem. Soc.* 2012; 134:5072–5075. [PubMed: 22390338]
16. Yin J, Wang C, Kong L, Cai S, Gao S. *Angew. Chem. Int. Ed.* 2012; 51:7786–7789.
17. (a) Burmeister HR, Bennett GA, Vesonder RF, Hesselti CW. *Antimicrob. Agents Ch.* 1974; 5:634–639. (b) Vesonder RF, Tjarks LW, Rohwedder WK, Burmeister HR, Laugal JA. *J. Antibiot.* 1979; 32:759–761. [PubMed: 541270] (c) Phillips NJ, Goodwin JT, Fraiman A, Cole RJ, Lynn DG. *J. Am. Chem. Soc.* 1989; 111:8223–8231.
18. For the proposed biosynthesis of equisetin see: Sims JW, Fillmore JP, Warner DD, Schmidt EW. *Chem. Comm.* 2005; 2:186–188. [PubMed: 15724180]
19. (a) Dickinson BC, Chang CJ. *Nat. Chem. Biol.* 2011; 7:504–511. [PubMed: 21769097] (b) Apel K, Hirt H. *Annu. Rev. Plan Biol.* 2004; 55:373–399. (c) Müller K, Gawlik I. *Free Radical Bio. Med.* 1997; 23:321–330. [PubMed: 9199895] (d) Corey EJ, Wang Z. *Tetrahedron Lett.* 1994; 35:539–542.
20. Migs, WJ.; de Jonge, CRH., editors. *Organic Synthesis by Oxidation with Metal Compounds*. New York: Plenum Press; 1986.
21. For reviews of IMDA reaction in total synthesis see: Juhl M, Tanner D. *Chem. Soc. Rev.* 2009; 38:2983–2992. [PubMed: 19847335] Takao K, Munakata R, Tadano K. *Chem. Rev.* 2005; 105:4779–4807. [PubMed: 16351062] Nicolaou KC, Snyder SA, Montagnon T, Vassilikogiannakis G. *Angew. Chem. Int. Ed. Engl.* 2002; 41:1668–1698. [PubMed: 19750686]
22. For consistency, the numbering of all carbon atoms in this manuscript is based on the carbon numbering of fusarisetin A.
23. For a recent revision of the stereochemical assignment of (+)-fusarisetin A see: Jang JH, Asami Y, Jang JP, Kim SO, Moon DO, Shin KS, Hashizume D, Muroi M, Saito T, Oh H, Kim BY, Osada H, Ahn JS. *J. Am. Chem. Soc.* 2012; 134:7194.
24. For equisetin synthesis see: Turos E, Audia JE, Danishefsky SJ. *J. Am. Chem. Soc.* 1989; 111:8231–8236. Burke LT, Dixon DJ, Ley SV, Rodriguez F. *Org. Lett.* 2000; 2:3611–3613. [PubMed: 11073657] Burke LT, Dixon DJ, Ley SV, Rodriguez F. *Org. Biomol. Chem.* 2005; 3:274–280. [PubMed: 15632969] Yuki K, Shindo M, Shishido K. *Tetrahedron Lett.* 2001; 42:2517–2519.
25. For reviews of atom economic and redox economic syntheses see: Wender PA, Verma VA, Paxton TJ, Pillow TH. *Acc. Chem. Res.* 2008; 41:40–49. [PubMed: 18159936] Wender PA, Miller BL. *Nature.* 2009; 460:197–201. [PubMed: 19587760] Burns NZ, Baran PS, Hoffmann RW. *Angew.*

- Chem. Int. Ed. 2009; 48:2854–2867. Newhouse T, Baran PS, Hoffmann RW. Chem. Soc. Rev. 2009; 38:3010–3021. [PubMed: 19847337] Gaich T, Baran PS. J. Org. Chem. 2010; 75:4657–4673. [PubMed: 20540516]
26. Chatterjee AK, Choi T-L, Sanders DP, Grubbs RH. J. Am. Chem. Soc. 2003; 125:11360–11370. [PubMed: 16220959]
27. (a) Julia M, Paris J-M. Tetrahedron Lett. 1973; 14:4833–4836.(b) Blakemore PR, Cole WJ, Kocienski PJ, Morley A. Synlett. 1998:26–28.
28. (a) Chen X, Millar JG. Synthesis. 2000:113–118.(b) Jacobs WC, Christmann M. Synlett. 2008:247–251.(c) Kim T, Mirafzal GA, Liu J-P, Bauld NL. J. Am. Chem. Soc. 1993; 115:7653–7664.(d) Tilley SD, Reber KP, Sorensen EJ. Org. Lett. 2009; 11:701–703. [PubMed: 19119873]
29. Turner CI, Williamson RM, Turner P, Sherburn MS. Chem. Commun. 2003:1610–1611.
30. For recent references on selected natural products possessing similar decalin functionalities see: Igarashi Y, Ogura H, Furihata K, Oku N, Indananda C, Thamchaipenet A. J. Nat. Prod. 2011; 74:670–674. [PubMed: 21388191] Lin T, Lin X, Lu C-H, Hu Z-Y, Huang W-Y, Huang Y-J, Shen Y-M. Eur. J. Org. Chem. 2009:2975–2982. Lang G, Blunt JW, Cummings NJ, Cole ALJ, Munro MHG. J. Nat. Prod. 2005; 68:810–811. [PubMed: 15921439] Tsukamoto S, Miura S, Yamashita Y, Ohta T. Bioorg. Med. Chem. Lett. 2004; 14:417–420. [PubMed: 14698172] Li JY, Strobel G, Harper J, Lobkovsky E, Clardy J. Org. Lett. 2000; 2:767–770. [PubMed: 10754679]
31. Wheeler MH, Stipanovic RD, Puckhaber LS. Mycol. Res. 1999; 103:967–973.
32. For selected reviews, see: Jasperse CP, Curran DP, Fevig TL. Chem. Rev. 1991; 91:1237–1286. Justicia J, Cienfuegos LÁ, Campaña AG, Miguel D, Jakoby V, Gansäuer A, Cuerva JM. Chem. Soc. Rev. 2011; 40:3525–3537. [PubMed: 21487573] Snider BB. Chem. Rev. 1996; 96:339–364. [PubMed: 11848756]
33. (a) Yoshida J, Nakatani S, Sakaguchi K, Ise S. J. Org. Chem. 1989; 54:3383–3389.(b) Iqbal J, Bhatia B, Nayyar NK. Tetrahedron. 1991; 47:6457–6468.(c) Chowdhury FA, Kajikawa S, Nishino H, Kurosawa K. Tetrahedron Lett. 1999; 40:3765–3768.
34. For initial studies, see: Jahn U. Chem. Commun. 2001:1600–1601. Jahn U, Hartmann P, Dix I, Jones PG. Eur. J. Org. Chem. 2001:3333–3355.
35. For related studies see: Jahn U, Müller M, Aussieker S. J. Am. Chem. Soc. 2000; 122:5212–5213. Wetter C, Jantos K, Woihe K, Studer A. Org. Lett. 2003; 5:2899–2902. [PubMed: 12889903] Vogler T, Studer A. Synthesis. 2006:4257–4265. Molawi K, Schulte T, Siegenthaler KO, Wetter C, Studer A. Chem.–Eur. J. 2005; 11:2335–2350. [PubMed: 15696581] Wetter C, Studer A. Chem. Commun. 2004:174–175. Schulte B, Studer A. Synthesis. 2006:2129–2138.
36. For applications see: Jahn U, Hartmann P, Dix I, Jones PG. Eur. J. Org. Chem. 2002:718–735. Siegenthaler KO, Schäfer A, Studer A. J. Am. Chem. Soc. 2007; 129:5826–5827. [PubMed: 17432857] Wienhöfer IC, Studer A, Rahman MT, Fukuyama T, Ryu I. Org. Lett. 2009; 11:2457–2460. [PubMed: 19422194]
37. For a review of TEMPO in living radical polymerizations see: Hawker CJ, Bosman AW, Harth E. Chem. Rev. 2001; 101:3661–3688. [PubMed: 11740918]
38. (a) Howell AR, Pattenden G. J. Chem. Soc., Perkin Trans. 1990; 1:2715–2720.(b) Gong J-X, Lin G, Sun W-B, Li C-C, Yang Z. J. Am. Chem. Soc. 2010; 132:16745–16746. [PubMed: 21049937]
39. Wang Y-F, Toh KK, Lee J-Y, Chiba S. Angew. Chem. Int. Ed. 2011; 50:5927–5931.
40. (a) Luche JL. J. Am. Chem. Soc. 1978; 100:2226–2227.(b) Gemal AL, Luche JL. J. Am. Chem. Soc. 1981; 103:5454–5459.
41. Huckin SN, Weiler L. J. Am. Chem. Soc. 1974; 96:1082–1087.
42. For selected examples see: Snider BB, Duvall JR. Org. Lett. 2004; 6:1265–1268. [PubMed: 15070313] Hulcoop DG, Burton JW. Chem. Comm. 2005:4687–4689. [PubMed: 16175293] Hájek M, Málek J. Synthesis-Stuttgart. 1976:315–318. Pattenden G. Chem. Soc. Rev. 1988; 17:361–382. Hirase K, Iwahama T, Sakaguchi S, Ishii Y. J. Org. Chem. 2002; 67:970–973. [PubMed: 11856046]
43. (a) Maillard B, Ingold KU, Scaiano JC. J. Am. Chem. Soc. 1983; 105:5095–5099.(b) Hermans I, Peeters J, Jacobs PA. Top. Catal. 2008; 50:124–132.
44. The relative stereochemistry of **25** and **26** were assigned based on the reported assignments of fusarisetin A and C₅-*epi*-fusarisetin A.

45. Movassaghi M, Schmidt MA. *Org. Lett.* 2005; 7:2453–2456. [PubMed: 15932221]
46. White KN, Konopelski JP. *Org. Lett.* 2005; 7:4111–4112. [PubMed: 16146364]
47. Interestingly, the CuCl-based reduction of **27** failed.
48. For reviews and recent examples of protecting group-free total synthesis see: Young IS, Baran PS. *Nat. Chem.* 2009; 1:193–205. [PubMed: 21378848] Baran PS, Richter JM. *J. Am. Chem. Soc.* 2005; 127:15394–15396. [PubMed: 16262402] McFadden RM, Stoltz BM. *J. Am. Chem. Soc.* 2006; 128:7738–7739. [PubMed: 16771478] Baran PS, Maimone TJ, Richter JM. *Nature*. 2007; 446:404–408. [PubMed: 17377577] Gademann K, Bonazzi S. *Angew. Chem. Int. Ed.* 2007; 46:5656–5658. Zhou QH, Chen XF, Ma DW. *Angew. Chem. Int. Ed.* 2010; 49:3513–3516. Hickmann V, Alcarazo M, Fürstner A. *J. Am. Chem. Soc.* 2010; 132:11042–11044. [PubMed: 20698670] Gerfaud T, Xie CS, Neuville L, Zhu JP. *Angew. Chem. Int. Ed.* 2011; 50:3954–3957.
49. Liang CC, Park AY, Guan JL. *Nat. Protoc.* 2007; 2:329–333. [PubMed: 17406593]
50. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. *Proc. Natl. Acad. Sci. USA.* 1996; 93:11669–11674. [PubMed: 8876194]
51. Fuchs E, Raghavan S. *Nat. Rev. Genet.* 2002; 3:199–209. [PubMed: 11972157]
52. (a) Yilmaz M, Christifori G. *Mol. Cancer Res.* 2010; 8:629–642. [PubMed: 20460404] (b) Friedl P, Gilmour D. *Nat. Rev. Mol. Cell Biol.* 2009; 10:445–457. [PubMed: 19546857] (c) Even-Ram S, Yamada KM. *Curr. Opin. Cell Biol.* 2005; 17:524–532. [PubMed: 16112853]
53. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. *Mol. Cancer Ther.* 2006; 5:1136–1144. [PubMed: 16731745]
54. All analogues were screened at 7.7 and 15.4 μM since at these concentrations we observed significant inhibition (ca 50%) of cell migration by (+)-fusarisetin A (see Figure 3).

Fig. 1. Retrosynthetic analysis of fusarisetin A (1) via equisetin (2) featuring a bioinspired oxidative radical cyclization (ORC) reaction (ROS: reactive oxygen species).

Fig. 2.

(+)-Fusarisetin A (**1**) reversibly inhibits the migration of MDA-MB-231 breast cancer cells in an *in vitro* scratch-wound assay. Cells grown as a confluent monolayer were scratched, photographed, and incubated with DMSO (control) and **1** (1 $\mu\text{g/mL}$ in DMSO). Micrographs (10 $\times$ magnification) are presented showing cell migration across the scratch. (A): wound created at the time of the scratch (time = 0 h); (B) cell migration in presence of DMSO (time= 48 h); (C) cell migration in presence of **1** (1 $\mu\text{g/mL}$), (time = 48 h); (D) wounded cells in panel C were rinsed with PBS to remove **1** and then incubated in fresh growth media for an additional 24 h.

Fig. 3. (+)-Fusarisetin A (**1**) inhibits the migration of MDA-MB-231 breast cancer cells in a Transwell migration assay. Cells were plated in a Boyden chamber with **1** or vehicle control (DMSO) for 24 h at the indicated concentrations. Amount of migrated cells is presented relative to the corresponding DMSO control.

Fig. 4. (+)-Fusarisetin A (**1**) inhibits cell migration in an *ex vivo* mouse skin assay. Ker: keratinocyte migration (red line); fib: fibroblast migration (blue line). (A) 5mm explant of mouse skin in a tissue culture dish (time = 0 days); (B) Migration of cells from skin explant incubated for 5 days in growth media containing control amount of DMSO; (C) Migration of cells from skin explant incubated for 5 days in growth media containing 10 µg/mL of fusarisetin A. The blue dotted line in Figure 4B shows the migration area of keratinocytes. Solid lines indicate migration distance.

Fig. 5. Screening of fusarisetin A (**1**), equisetin (**2**) and selected synthetic intermediates in a scratch-wound assay at two different concentrations (7.7 and 15.4 μM). Values are given as relative migration in comparison to DMSO control.

Scheme 1.

Synthesis of the *trans*-decalin moiety and study of the TEMPO-induced ORC. Reagents and conditions: (a) methacrolein (2.0 equiv), Grubbs^{2nd} gen. catalyst (5 mol%), CH₂Cl₂, 50 °C, 24 h, 75% (90% brsm); (b) SeO₂ (3 mol%), ^tBuOOH (4.0 equiv), salicylic acid (0.1 equiv), CH₂Cl₂, 96 h, then IBX (1.4 equiv), DMSO, 1.5 h, 65%; (c) **8** (1.0 equiv), *n*-BuLi (1.0 equiv), THF, -60 °C, 1 h, then -78 °C, **ent-7**, (see SI), 62%; (d) I₂ (5 mol%), sunlamp (visible light), CH₂Cl₂, 5 min, then -78 °C, Et₂AlCl (1.0 equiv), 24 h, 82%; (e) activated zinc dust (3.0 equiv), ethyl bromoacetate (1.2 equiv), PhH, 45 min, 90 °C; (f) IBX (2.0 equiv), DMSO, 80 °C, 10 min, 91% for 2 steps; (g) **10** (3.0 equiv), PhMe, reflux, 12 h; (h) HF (48% in H₂O, 10 equiv), MeCN, 15 min, 43% over 2 steps; (i) NaOMe (5.0 equiv), MeOH, 10 min, 100 % combined yield (dr = ca 1:1); (j) TBSCl (1.5 equiv), imidazole (2.0 equiv), CH₂Cl₂, 12 h, 90%; (k) **13** or Mn(OAc)₃ (2.0 equiv), TEMPO (3.0 equiv), DMF, microwave, 100 °C, 35%; (l) activated zinc dust (20 equiv), AcOH/THF/H₂O (3:1:1), 80 °C, 3 h, 30%.

Scheme 2.

First generation total synthesis of (–)-fusarisetin A (**ent-1**) via a TEMPO-mediated ORC. Reagents and conditions: (a) LiHMDS (1.5 equiv), 1,2-DME, -78°C , 30 min, then 0°C , TEMPO (1.05 equiv), Cp_2FePF_6 (**13**, 2.0 equiv), 5 min, 99%; (b) **ent-18**, DMAP (2.0 equiv), PhMe, $4\text{\AA}$ MS, 90°C , 36 h, 70% (d.r. = ca 1:1); (c) *m*CPBA (1.2 equiv), CH_2Cl_2 , 0°C , 15 min, 95%; (d) NaBH_4 (1.2 equiv), $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ (1.5 equiv), MeOH, -20°C (d.r. = ca 4:1); (e) NaOMe (5.0 equiv), MeOH, 10 min, 42% for 2 steps.

Scheme 3.

Model studies of metal-promoted ORC reactions. Reagents and conditions: (a) NaH (1.1 equiv), THF, 0 °C, 10 min; then *n*-BuLi (1.05 equiv), 0 °C, 10 min; crotyl bromide (1.07 equiv), 0 °C to RT, 2 h, 92%; (b) *N*-methyl glycine methyl ester•HCl (2.0 equiv), DMAP (2.0 equiv), Et₃N (3.0 equiv), PhMe, 110 °C, 12 h, 50%; (c) NaOMe (4.0 equiv), MeOH, 2 h, 97%.

Scheme 4.

Scalable total synthesis of (-)-equisetin (**2**) and (+)-fusarisetin A (**1**). Reagents and conditions: (a) activated zinc dust (5.0 equiv), ethyl bromoacetate (3.0 equiv), PhH, 90 °C, 45 min; (b) Dess-Martin periodinane (2.0 equiv), CH₂Cl₂, RT, 2 h, 92% for 2 steps; (c) KOH (5.6 equiv), EtOH, RT, 96 h, then **18** (1.2 equiv), HATU (1.1 equiv), CH₂Cl₂, DMF, 0 °C, *i*Pr₂NEt (3.0 equiv), then RT, 2 h, 90%; (d) NaOMe (5.0 equiv), MeOH, RT, 10 min, 100% combined yield (dr = 1:1); (e) CAN (1.0 equiv), AcOH, O₂, RT, 3 h, then silica pad, thiourea (10 equiv), MeOH, 70 °C, 1 h, 62% combined yield (dr = 1.3:1).

[Table 1]

Selected conditions for the conversion of **24** to **25** and **26** via a metal-promoted ORC reaction.

Entry	Oxidant	Temp. °C)	Time	Yield of 25	Reduct- ant	Yield of 26
1	Co(OAc) ₂	70	5 min	20%	CuCl	80%
2	Co(OAc) ₂	70	5 min	20%	thiourea	n.r./ <i>[c]</i>
3	Co(OAc) ₂	25	4 h	10%	CuCl	79%
4	Co(OAc) ₂ / <i>[d]</i>	25	12 h	n.r.	-	-
5	CoCl ₂	25	12 h	n.r.	-	-
6	Mn(OAc) ₃	25	12 h	5%	-	-
7	CeCl ₃	25	12 h	trace	-	-
8	Fe(III)/ <i>[e]</i>	25	12 h	15%	CuCl	81%
9	CAN	25	3 h	57%	CuCl	82%
10	CAN	-20	18 h	57%	CuCl	79%
11	CAN	70	5 min	20%	-	-
12	CAN/ <i>[f]</i>	25	3 h	40%	CuCl	80%
13	CAN/ <i>[g]</i>	70	3 h	30%	CuCl	81%

[a,b] For a detailed screening study see SI;

[b] all the reactions were performed under 1 bar of oxygen and 1 equiv of the oxidant in AcOH unless otherwise noted; Yields of **25** and **26** refer to isolated products;

[c] no reaction occurred;

[d] *i*PrOH was used as the solvent;

[e] ferrocenium hexafluorophosphate;

[f] 0.1 equiv of CAN was used;

[g] reaction opened to air. CAN = cerium(IV) ammonium nitrate.